Title
Comorbidity of common mental disorders with cancer and their treatment gap: Findings from the World Mental Health Surveys
Date Issued
01 January 2014
Access level
open access
Resource Type
journal article
Author(s)
Nakash O.
Levav I.
Aguilar-Gaxiola S.
Alonso J.
Andrade L.H.
Angermeyer M.C.
Bruffaerts R.
Caldas-De-Almeida J.M.
Florescu S.
De Girolamo G.
Gureje O.
He Y.
Hu C.
De Jonge P.
Karam E.G.
Kovess-Masfety V.
Medina-Mora M.E.
Moskalewicz J.
Murphy S.
Nakamura Y.
Posada-Villa J.
Stein D.J.
Taib N.I.
Zarkov Z.
Kessler R.C.
Scott K.M.
Publisher(s)
John Wiley & Sons
Abstract
Objective This study aimed to study the comorbidity of common mental disorders (CMDs) and cancer, and the mental health treatment gap among community residents with active cancer, cancer survivors and cancer-free respondents in 13 high-income and 11 low-middle-income countries. Methods Data were derived from the World Mental Health Surveys (N = 66,387; n = 357 active cancer, n = 1373 cancer survivors, n = 64,657 cancer-free respondents). The World Health Organization/Composite International Diagnostic Interview was used in all surveys to estimate CMDs prevalence rates. Respondents were also asked about mental health service utilization in the preceding 12 months. Cancer status was ascertained by self-report of physician's diagnosis. Results Twelve-month prevalence rates of CMDs were higher among active cancer (18.4%, SE = 2.1) than cancer-free respondents (13.3%, SE = 0.2) adjusted for sociodemographic confounders and other lifetime chronic conditions (adjusted odds ratio (AOR) = 1.44, 95% CI 1.05-1.97). CMD rates among cancer survivors (14.6%, SE = 0.9) compared with cancer-free respondents did not differ significantly (AOR = 0.95, 95% CI 0.82-1.11). Similar patterns characterized high-income and low-middle-income countries. Of respondents with active cancer who had CMD in the preceding 12 months, 59% sought services for mental health problems (SE = 5.3). The pattern of service utilization among people with CMDs by cancer status (highest among persons with active cancer, lower among survivors and lowest among cancer-free respondents) was similar in high-income (64.0%, SE = 6.0; 41.2%, SE = 3.0; 35.6%, SE = 0.6) and low-middle-income countries (46.4%, SE = 11.0; 22.5%, SE = 9.1; 17.4%, SE = 0.7). Conclusions Community respondents with active cancer have higher CMD rates and high treatment gap. Comprehensive cancer care should consider both factors. Copyright © 2013 John Wiley & Sons, Ltd.
Start page
40
End page
51
Volume
23
Issue
1
Language
English
OCDE Knowledge area
Psiquiatría
Oncología
Epidemiología
Subjects
DOI
Scopus EID
2-s2.0-84891635214
PubMed ID
Source
Psycho-Oncology
ISSN of the container
1099-1611
Sponsor(s)
AstraZeneca
Bristol-Myers Squibb
Eli Lilly and Company
European Commission EAHC 20081308, QLG5-1999-01042, SANCO 2004123
Fogarty International Center FIRCA R03-TW006481
GlaxoSmithKline
Health Research Council of New Zealand
National Institute of Mental Health R01 MH070884, U01-MH60220
Novartis
Pfizer
Robert Wood Johnson Foundation 044708
Roche
Substance Abuse and Mental Health Services Administration
National Institute of Mental Health R01MH069864 NIMH
Sources of information:
Directorio de Producción Científica
Scopus